Avxl stock price forecast traders are positioning with tight

Traders are positioning with tight stop-loss orders to manage biotech-sector risk. We recently published an article titled Jim Cramer’s Lightning Rounds: 9 Stocks in Focus . In this article, we are going to take a look at where Anavex Life Sciences Corp. (NASDAQ:AVXL) stands against the other stocks. In October 2024, Anavex Life Sciences reported positive initial biomarker results from Part A of an ongoing mid-stage study of ANAVEX 3-71 for schizophrenia. This multiple ascending dose portion of the phase II ANAVEX 3-71-SZ-001 study, evaluated two oral, daily doses of the candidate (90 mg or 180 mg) in 16 patients for 10 days. Analysts note AVXL stock price forecast could benefit from positive readouts in neurodegenerative trials; probability-adjusted models suggest $9.50 potential within one quarter.